



## Clinical trial results:

### A multicenter phase II study to determine the efficacy of capecitabine as first line monochemotherapy in patients with HER2 negative, medium-risk, metastatic breast cancer

#### Summary

EudraCT number	2005-000074-51
Trial protocol	DE
Global end of trial date	25 June 2009

#### Results information

Result version number	v1 (current)
This version publication date	23 December 2021
First version publication date	23 December 2021
Summary attachment (see zip file)	MoniCa CSR Synopsis (GBG 39 - MoniCa Clinical Study Report - Synopsis (29.01.2015) - fully signed.pdf)

#### Trial information

##### Trial identification

Sponsor protocol code	GBG 39
-----------------------	--------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00196820
WHO universal trial number (UTN)	-

Notes:

##### Sponsors

Sponsor organisation name	GBG Forschungs GmbH
Sponsor organisation address	Martin Behaim Str. 12, Neu-Isenburg, Germany,
Public contact	Medicine and Research, GBG Forschungs GmbH, +49 610274800, publications@gbg.de
Scientific contact	Medicine and Research, GBG Forschungs GmbH, +49 610274800, publications@gbg.de

Notes:

##### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

---

**Results analysis stage**

---

Analysis stage	Final
Date of interim/final analysis	14 August 2009
Is this the analysis of the primary completion data?	Yes
Primary completion date	31 March 2009
Global end of trial reached?	Yes
Global end of trial date	25 June 2009
Was the trial ended prematurely?	Yes

Notes:

---

**General information about the trial**

---

Main objective of the trial:

To determine the time to disease progression in patients with HER2 negative metastatic breast cancer after 1st line monochemotherapy with capecitabine

Protection of trial subjects:

The trial protocol including amendments, the patient information and the informed consent were reviewed and approved from a properly constituted IRB/IEC for each site prior to the study start. The trial was in compliance with the International Conference on Harmonization (ICH) - Harmonized Tripartite Guideline for Good Clinical Practice (GCP) (E6), and the Commission Directives in the European Community as well as with the applicable German national laws and regulations, and with Declaration of Helsinki and its revisions in all aspects of preparation, monitoring, reporting, auditing, and archiving.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	20 July 2005
Long term follow-up planned	Yes
Long term follow-up rationale	Scientific research
Long term follow-up duration	10 Years
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

---

**Population of trial subjects**

---

**Subjects enrolled per country**

Country: Number of subjects enrolled	Germany: 165
Worldwide total number of subjects	165
EEA total number of subjects	165

Notes:

---

**Subjects enrolled per age group**

---

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0

Adults (18-64 years)	81
From 65 to 84 years	80
85 years and over	4

## Subject disposition

### Recruitment

Recruitment details:

Approximately 2.5 years (Q-III 2005 –Q-I 2008) in 35 sites in Germany. 200 patients were planned. The study was stopped after 165 patients were enrolled because of a change of standard of care for 1st line metastatic breast cancer. Eventually, 161 patients were treated and included for efficacy and safety analyses.

### Pre-assignment

Screening details:

Female/male >18yrs with histologically confirmed BC, locally advanced or metastatic BC not suitable for surgery or RT alone, HER2-, and measurable/nonmeasurable target lesions acc. to WHO; previously treated with adjuvant CT (without capecitabine) or adjuvant/palliative ET, bisphosphonates or immunotherapies; >=4wks since RT with full recovery

### Pre-assignment period milestones

Number of subjects started	165
Number of subjects completed	161

### Pre-assignment subject non-completion reasons

Reason: Number of subjects	Disease progression: 1
Reason: Number of subjects	Consent withdrawn by subject: 2
Reason: Number of subjects	patient wish: 1

### Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

<b>Arm title</b>	Capecitabine
------------------	--------------

Arm description:

Capecitabine 2000 mg/m<sup>2</sup> orally on days 1-14 q day 22.

Arm type	Experimental
Investigational medicinal product name	Capecitabine
Investigational medicinal product code	
Other name	Xeloda®
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

2000 mg/m<sup>2</sup> orally on days 1-14 q day 22

<b>Number of subjects in period 1<sup>[1]</sup></b>	Capecitabine
Started	161
Completed	126
Not completed	35
Physician decision	3
Consent withdrawn by subject	5
Adverse event, non-fatal	24
patient wish	3

---

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: 165 patients were enrolled, but 4 did not start Treatment. 161 started Treatment and are reported in the baseline period

## Baseline characteristics

### Reporting groups

Reporting group title	Overall trial
-----------------------	---------------

Reporting group description: -

Reporting group values	Overall trial	Total	
Number of subjects	161	161	
Age categorical			
Units: Subjects			
In utero		0	
Preterm newborn infants (gestational age < 37 wks)		0	
Newborns (0-27 days)		0	
Infants and toddlers (28 days-23 months)		0	
Children (2-11 years)		0	
Adolescents (12-17 years)		0	
Adults (18-64 years)		0	
From 65-84 years		0	
85 years and over		0	
Age continuous			
Units: years			
median	65		
full range (min-max)	37 to 90	-	
Gender categorical			
Units: Subjects			
Female	160	160	
Male	1	1	

## End points

### End points reporting groups

Reporting group title	Capecitabine
Reporting group description: Capecitabine 2000 mg/m <sup>2</sup> orally on days 1-14 q day 22.	

### Primary: time to disease progression (TTP)

End point title	time to disease progression (TTP) <sup>[1]</sup>
End point description:	

End point type	Primary
----------------	---------

End point timeframe:

TTP is defined as time (in weeks) from the registration until disease progression (or death due to any cause). Pts who had not experienced progression until analysis were censored at the date of last tumor assessment, last FU date or last date drug log.

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses for this end point.

The median TTP was 7.9 months (31.6 weeks; 95% confidence interval (CI) 26.9–36.3), which was significantly longer than the hypothesis of a minimum of 25 weeks ( $p < 0.05$ ).

<b>End point values</b>	Capecitabine			
Subject group type	Reporting group			
Number of subjects analysed	161 <sup>[2]</sup>			
Units: week				
number (confidence interval 95%)	31.6 (26.9 to 36.3)			

Notes:

[2] - At database lock 130 disease progressions and 72 deaths (3 without preceding progression) events

### Statistical analyses

No statistical analyses for this end point

### Secondary: Overall survival

End point title	Overall survival
End point description:	

End point type	Secondary
----------------	-----------

End point timeframe:

Overall survival is the time (in weeks) from the registration until death due to any cause; patients lost to follow-up was censored at the date of the last contact.

<b>End point values</b>	Capecitabine			
Subject group type	Reporting group			
Number of subjects analysed	161 <sup>[3]</sup>			
Units: week				
number (confidence interval 95%)	74.22 (60.59 to 87.85)			

Notes:

[3] - 72 Events/89 censored

### Statistical analyses

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

All adverse events occurring during the study treatment period were reported

Adverse event reporting additional description:

Only drug-related SAEs are reported;

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	n.a.
-----------------	------

Dictionary version	0
--------------------	---

### Reporting groups

Reporting group title	Capecitabine
-----------------------	--------------

Reporting group description: -

<b>Serious adverse events</b>	Capecitabine		
Total subjects affected by serious adverse events			
subjects affected / exposed	12 / 161 (7.45%)		
number of deaths (all causes)	73		
number of deaths resulting from adverse events			
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 161 (0.62%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
weak condition (fatigue)			
subjects affected / exposed	1 / 161 (0.62%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
decrease of general condition			
subjects affected / exposed	1 / 161 (0.62%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Diarrhoea			

subjects affected / exposed	3 / 161 (1.86%)		
occurrences causally related to treatment / all	3 / 3		
deaths causally related to treatment / all	0 / 0		
gastrointestinal bleeding			
subjects affected / exposed	1 / 161 (0.62%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
hemorrhagic gastritis			
subjects affected / exposed	1 / 161 (0.62%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
diarrhea, nausea, vomitus			
subjects affected / exposed	1 / 161 (0.62%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
dizziness and exsiccosis, anorexia grade III			
subjects affected / exposed	1 / 161 (0.62%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Pneumonia			
subjects affected / exposed	1 / 161 (0.62%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Skin and subcutaneous tissue disorders			
Hand foot skin reaction			
subjects affected / exposed	2 / 161 (1.24%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Capecitabine		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	135 / 161 (83.85%)		
Vascular disorders			
Thrombosis			
subjects affected / exposed	13 / 161 (8.07%)		
occurrences (all)	13		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	82 / 161 (50.93%)		
occurrences (all)	82		
Leukopenia			
subjects affected / exposed	103 / 161 (63.98%)		
occurrences (all)	103		
Neutropenia			
subjects affected / exposed	1 / 161 (0.62%)		
occurrences (all)	1		
Thrombopenia			
subjects affected / exposed	45 / 161 (27.95%)		
occurrences (all)	45		
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	55 / 161 (34.16%)		
occurrences (all)	55		
Pain			
subjects affected / exposed	19 / 161 (11.80%)		
occurrences (all)	19		
Oedema			
subjects affected / exposed	18 / 161 (11.18%)		
occurrences (all)	18		
Gastrointestinal disorders			
Nausea			
subjects affected / exposed	48 / 161 (29.81%)		
occurrences (all)	48		
Diarrhoea			
subjects affected / exposed	33 / 161 (20.50%)		
occurrences (all)	33		

Stomatitis			
subjects affected / exposed	23 / 161 (14.29%)		
occurrences (all)	23		
Vomiting			
subjects affected / exposed	17 / 161 (10.56%)		
occurrences (all)	17		
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	33 / 161 (20.50%)		
occurrences (all)	33		
Skin and subcutaneous tissue disorders			
Hand-foot syndrome			
subjects affected / exposed	60 / 161 (37.27%)		
occurrences (all)	60		
Alopecia			
subjects affected / exposed	24 / 161 (14.91%)		
occurrences (all)	24		
Nail changes			
subjects affected / exposed	12 / 161 (7.45%)		
occurrences (all)	12		
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	16 / 161 (9.94%)		
occurrences (all)	16		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

200 patients were planned. The study was stopped after 165 patients were enrolled because of a change of standard of care for 1st line metastatic breast cancer.

Notes:

---

### Online references

<http://www.ncbi.nlm.nih.gov/pubmed/20797843>